|
1.
|
Mani A and Gelmann EP: The
ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol.
23:4776–4789. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Bowerman B and Kurz T: Degrade to create:
developmental requirements for ubiquitin-mediated proteolysis
during early C. elegans embryogenesis. Development.
133:773–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Naujokat C and Hoffmann S: Role and
function of the 20S proteasome in proliferation and
apoptosis. Lab Invest. 82:965–980. 2002.
|
|
4.
|
Collins GA and Transey WP: The proteasome:
a utility for transcription. Current Opin Genet Dev. 16:197–202.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Tylor C and Jobin C: Ubiquitin protein
modification and signal transduction: Implications for inflammatory
bowel diseases. Inflamm Bowel Dis. 11:1097–1107. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Asher G, Bercovich Z, Tsvetkov P, Shaul Y
and Kahana C: 20S proteasomal degradation of ornithine
decarboxylase is regulated by NQO1. Mol Cell. 17:645–655. 2005.
|
|
7.
|
Strehl B, Seifert U, Krüger E, Heink S,
Kuckelkorn U and Kloetzel PM: Interferon-γ, the functional
plasticity of the ubiquitin-proteasome system, and MHC class I
antigen processing. Immunol Rev. 207:19–30. 2005.
|
|
8.
|
Sakai N, Sawada MT and Sawada H:
Non-traditional roles of ubiquitin-proteasome system in
fertilization and gametogenesis. Int J Biochem Cell Biol.
36:776–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Heinemeyer W, Kleinschmidt JA, Saidowsky
J, Escher C and Wolf DH: Proteinase yscE, the yeast
proteasome/multicatalytic-multifunctional proteinase: Mutant
unravels its function in stress proteolysis and uncovers its
necessity for cell survival. EMBO J. 10:555–562. 1991.
|
|
10.
|
Shinohara K, Tomioka M, Nakano H, Toné S,
Ito H and Kawashima S: Apoptosis induction resulting from
proteasome inhibition. Biochem J. 317:385–388. 1996.
|
|
11.
|
Delic J, Masdehors P, Omura S, Cosset JM,
Dumont J, Binet J and Magdelenat H: The proteasome inhibitor
lactacystin induces apoptosis and sensitizes chemo- and
radioresistant human lymphocytic leukemia lymphocytes to TNF-α
initiated apoptosis. Br J Cancer. 77:1103–1107. 1998.PubMed/NCBI
|
|
12.
|
Ma MH, Yang HH, Parker K, et al: The
proteasome inhibitor PS-341 markedly enhances sensitivity of
myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res.
9:1136–1144. 2003.PubMed/NCBI
|
|
13.
|
Teicher BA: Newer cytotoxic agents:
attacking cancer broadly. Clin Cancer Res. 14:1610–1617. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Rajkumar SV, Richardson PG, Hideshima T
and Anderson KC: Proteasome inhibition as a novel therapeutic
target in human cancer. J Clin Oncol. 23:630–639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Obeng EA, Carlson LM, Gutman DM,
Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce
a terminal unfolded protein response in multiple myeloma cells.
Blood. 107:4907–4919. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Velazquez OC, Lederer HM and Rombeau JL:
Butyrate and the colonocyte: production, absorption, metabolism,
and therapeutic implications. Adv Exp Med Biol. 427:123–134. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Macfarlane GT and Gibson GR:
Microbiological aspects of the production of short-chain fatty
acids in the large bowel. Physiological and Clinical Aspects of
Short-Chain Fatty Acids. Cambridge University Press; Cambridge: pp.
87–105. 1995
|
|
18.
|
Pouillart PR: Role of butyric acid and its
derivatives in the treatment of colorectal cancer and
hemoglobinopathies. Life Sci. 63:1739–1760. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kruth J, Defer N and Tichonicky L:
Molecular and cellular action of butyrate. C R Seances Soc Biol
Fil. 186:12–25. 1992.
|
|
20.
|
Velazquez OC and Rombeau JL: Butyrate:
potential role in colon cancer prevention and treatment. Adv Exp
Med Biol. 427:169–181. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Abaza MSI, Bahman A and Al-Attiyah R:
Roscovitine synergizes with conventional chemotherapeutic drugs to
induce efficient apoptosis of human colorectal cancer cells. World
J Gasteroenterol. 14:5162–5175. 2008. View Article : Google Scholar
|
|
22.
|
Lam PK, To EW, Chan ES, Liew CT, Lung IW
and King WK: In vitro modulation of head and neck cell
growth by human recombinant interferon α and 13-cis-retinoic acid.
Br J Biomed Sci. 58:226–229. 2001.
|
|
23.
|
Abaza MSI, Al-Saffar AM, Al-Sawan SM and
Al-Attiyah R: c-myc antisense oligonucleotides sensitize
human colorectal cancer cells to chemotherapeutic drugs. Tumor
Biol. 29:287–303. 2008. View Article : Google Scholar
|
|
24.
|
Fan XM, Wong BC, Wang WP, et al:
Inhibition of proteasome function induced apoptosis in gastric
cancer. Int J Cancer. 93:481–488. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng T, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: release of cytochrome c from mitochondria blocked.
Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Wilson MR: Apoptosis: unmasking the
executioner. Cell Death Differ. 5:646–652. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Schendel SL, Montal M and Reed JC: Bcl-2
family proteins as ion-channels. Cell Death Diff. 5:372–380. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lee S, Christakos S and Small MB:
Apoptosis and signal transduction: clues to a molecular mechanisms.
Curr Opin Cell Biol. 5:286–289. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Lopes UG, Erhardt P, Yao R and Cooper GM:
p53-dependent induction of apoptosis by proteasome inhibitors. J
Biol Chem. 272:12893–12896. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Blagosklonny MV, Wu GS, Omura S and
El-Deriry WS: Proteasome-dependent regulation of
p21Waf1/Cip1 expression. Biochem Biophys Res Commun.
227:564–569. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Pagano M, Tam SW, Theodoras AM,
Beer-Romero P, Del Sal G, Chau V, Yew PR, et al: Role of the
ubiquitin-proteasome pathway in regulating abundance of the
cyclin-dependent kinase inhibitor p27. Science. 269:682–685. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Orlowski RZ: The role of the
ubiquitin-proteasome pathway in apoptosis. Cell Death Diff.
6:303–313. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Finucane DM, Wetzel-Bossy E, Waterhouse
NJ, Cotter TG and Green DR: Bax-induced caspase activation and
apoptosis via cytochrome c release from mitochondria is
inhibitable by Bcl-XL. J Biol Chem. 274:2225–2233. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Ciechanover A: Proteolysis from the
lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol.
6:79–87. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Admas J: The proteasome: a suitable
antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Richardson PG, Sonneveld P, Schuster MW,
et al: Bortezomib or high-dose dexamethsome for relapsed multiple
myeloma. N Engl J Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Goy A, Younes A, McLaughlin P, et al:
Phase II study of proteasome inhibitor bortezomib in relapsed or
refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 23:667–675.
2005.
|
|
39.
|
Hacihanefioglu A, Tarkun P and Gonullu E:
Acute severe cardiac failure in a myeloma patient due to proteasome
inhibitor bortezomib. Int J Hematol. 88:219–222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Enrico O, Gabriele B, Nadia C, et al:
Unexpected cardiotoxicity in haematological bortezomib-treated
patients. Br J Haematol. 138:396–397. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Richardson PG, Briemberg H, Jagannath S,
et al: Frequency, characteristics, and reversibility of peripheral
neuropathy during treatment of advanced multiple myeloma with
bortezomib. J Clin Oncol. 24:3113–3120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Lonial S, Waller EK, Richardson PG, et al:
Risk factors and kinetics of thrombocytopenia associated with
bortezomib for relapsed, refractory multiple myeloma. Blood.
106:3777–3784. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Papandreou CN, Daliani DD, Nix D, et al:
Phase I trial of the proteasome inhibitor bortezomib in patients
with advanced solid tumors with observations in
androgen-independent prostate cancer. J Clin Oncol. 22:2108–2121.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
McConkey D and Zhu K: Mechanisms of
proteasome inhibitor action and resistance in cancer. Drug Resist
Updates. 11:164–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Andrews PA and Howell SB: Cellular
pharmacology of cisplatin: perspectives on mechanisms of acquired
resistance. Cancer Cell. 2:35–43. 1990.PubMed/NCBI
|
|
46.
|
Miller AA, Kurschel E, Osieka P and
Schmidt CG: Clinical pharmacology of sodium butyrate in patients
with acute leukemia. Eur J Cancer Clin Oncol. 23:1283–1287. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Giuliano M, Lauricella M, Calvaruso G,
Carabillo M, Emanuele S, Vento R and Tesoriere G: The apoptotic
effects and synergistic interaction of sodium butytrate and MG132
in human retinoblastoma Y79 cells. Cancer Res. 59:5586–5595.
1999.PubMed/NCBI
|
|
48.
|
Kim OH, Lim JH, Woo KJ, Kim YH, Jin IN,
Han ST, Park JW and Kwon TK: Influence of p53 and
p21waf1 expression on G2/M phase arrest of
colorectal carcinoma HCT116 cells to proteasome inhibitors. Int J
Oncol. 24:935–941. 2004.PubMed/NCBI
|
|
49.
|
Wu WK, Sung JY, Wu YC, Li ZJ, Yu L and Cho
CH: Bone morphogenetic protein signaling is required for the
anti-mitogenic effect of the proteasome inhibitor MG-132 on colon
cancer cells. Br J Pharmacol. 154:632–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Denlinger CE, Keller MD, Mayo MW, Broad RM
and Jones DR: Combined proteasome and histone deacetylase
inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg.
127:1087–1086. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Abramova M, Pospelova TV, Nikulenkov FP,
Hollander CM, Fornace AJ Jr and Pospelov VA: G1/S arrest
induced by deacetylase inhibitor sodium butyrate in
E1A+Ras-transformed cells is mediated through down-regulation of
E2F activity and stabilization of β-catenin. J Biol Chem.
281:21040–21051. 2006.
|
|
52.
|
Lauricella M, Calvaruso G, Giuliano M,
Carabillo M, Emanuele S and Vento R: Synergistic cytotoxic
interactions between butyrate, MG132 and camptothecin in human
retinoblastoma Y79 cells. Tumor Biol. 21:337–348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Kitagawa H, Tani E, Ikemoto H, Ozaki I,
Nakano A and Omura S: Proteasome inhibitors induce
mitochondria-independent apoptosis in human glioma cells. FEBS
Lett. 443:181–186. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan
KH and Seth P: Promoting apoptosis: a novel activity associated
with the cyclin-dependent kinase inhibitor p27. Cancer Res.
57:5441–5446. 1997.PubMed/NCBI
|
|
55.
|
Timmerbeul I, Garrett-Engele CM, Kossatz
U, et al: Testing the importance of p27 degradation by the SCFskp2
pathway in murine models of lung and colon cancer. Proc Natl Acad
Sci USA. 103:14009–14014. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Pandit B and Gartel AL: New potential
anti-cancer agents synergize with bortezomib and ABT-737 against
prostate cancer. Prostate. 70:825–833. 2010.PubMed/NCBI
|
|
57.
|
Chauhan D, Singh AV, Ciccarelli B,
Richardson PG, Palladino MA and Anderson KC: Combination of novel
proteasome inhibitor NPI-5552 and lenalidomide trigger in
vitro and in vivo synergistic cytotoxicity in multiple
myeloma. Blood. 115:834–845. 2009.PubMed/NCBI
|
|
58.
|
Matondo M, Bousquet-Dubouch MP, Gallay N,
et al: Proteasome inhibitor-induced apoptosis in acute myeloid
leukemia: A correlation with proteasome status. Leuk Res.
34:498–506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Yuan JY, Shaham S, Ledoux S, Ellis HM and
Horvitz HR: The C. elegans cell death gene ced-3 encodes a
protein similar to mammalian interleukin-1 beta-converting enzyme.
Cell. 75:641–652. 1993.
|
|
60.
|
Nicholson DW and Thornberry NA: Caspases:
killer proteases. Trends Biochem Sci. 22:299–306. 1997. View Article : Google Scholar
|
|
61.
|
Talanian RV, Quinlan C, Trautz S, et al:
Substrate specificities of caspase family proteases. J Biol Chem.
272:9677–9682. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Fuchs E and Weber K: Intermediate
filaments: structure, dynamics, function, and disease. Ann Rev
Biochem. 63:345–382. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Germain M, Affar EB, D’Amours D, Dixit VM,
Salvesen GS and Poirier GG: Cleavage of auto-modified
poly(ADP-ribose)polymerase during apoptosis. Evidence for
involvement of caspase-7. J Biol Chem. 274:28379–28384. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Cuvillier O, Rosenthal DS, Smulson ME and
Spiegel S: Shingosine-1-phosphate inhibits activation of caspases
that cleave poly(ADP-ribose) polymerase and lamins during Fas- and
ceramide-mediated apoptosis in Jurkat lymphocytes. J Biol Chem.
273:29010–29016. 1998. View Article : Google Scholar
|
|
65.
|
Reed JC: Bcl-2 and the regulation of
programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Liu X, Kim CN, Yang J, Jemmerson R and
Wang X: Induction of apoptotic program in cell-free extracts:
requirement for dATP and cytochrome c. Cell. 96:147–157.
1999.PubMed/NCBI
|
|
67.
|
Chandra J, Niemer I, Gilbreath J, et al:
Proteasome inhibitors induce apoptosis in glucocorticoid-resistant
chronic lymphocytic leukemic lymphocytes. Blood. 92:4220–4229.
1998.PubMed/NCBI
|
|
68.
|
Chen YR, Wang X, Templeton D, Davis RJ and
Tan TH: The role of c-jun N-terminal kinase (JNK) in apoptosis
induced by ultraviolet C and λ radiation. J Biol Chem. 31929–31936.
1996.
|
|
69.
|
Williams SA and McConkey DJ: The
proteasome inhibitor bortezomib stabilizes a novel active form of
p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res.
63:7338–7344. 2003.PubMed/NCBI
|
|
70.
|
Medina V, Edmonds B, Young GP, James R,
Appleton S and Zalewski PD: Induction of caspase-3 protease
activity and apoptosis by butyrate and trichostatin-A (inhibitors
of histone deacetylase): dependence on protein synthesis and
synergy with a mitochondrial/cytochrome c-dependent pathway.
Cancer Res. 57:3697–3707. 1997.PubMed/NCBI
|
|
71.
|
Lara PN, Davies AM, Mack PC, Mortenson MM,
Bold RJ, Gumerlock PH and Gandara DR: Proteasome inhibition with
PS-341 (bortezomib) in lung cancer therapy. Sem Oncol. 31:40–46.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Zhu H, Zhang L, Dong F, et al: Bik/NBK
accumulation correlates with apoptosis-induction by bortezomib
(PS-341, Velcade) and other proteasome inhibitors. Oncogene.
24:4993–4999. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Goldstein JC, Waterhouse NJ, Juin P, Evan
GI and Green DR: The coordinate release of cytochrome c during
apoptosis is rapid, complete and kinetically invariant. Nat Cell
Biol. 2:156–162. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Daly K and Shirazi-Beechey SP: Microarray
analysis of butyrate-regulated genes in colonic epithelial cells.
DNA Cell Biol. 25:49–62. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Davie JR: Inhibition of histone
deacetylase activity by butyrate. J Nutr. 133(Suppl 7):
2485s–2493s. 2003.PubMed/NCBI
|
